{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-276738","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-22T12:14:24+00:00","discovered_at":"2026-06-22T12:15:00.268458+00:00","generated_at":"2026-06-22T12:15:18.754748+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Taysha completes REVEAL pivotal trial dosing; longer-term data shows durable functional gains in Rett syndrome","bullets":["Completed dosing of 17 patients in REVEAL pivotal trial; topline 6-month interim data and FDA feedback expected 1H 2027.","100% of 12 REVEAL Part A patients gained/regained ≥1 developmental milestone by 12 months post-TSHA-102.","No treatment-related SAEs or DLTs across 29 patients dosed as of June 2026 cutoff.","310 total functional gains observed ≥12 months post-treatment (~26 per patient) across core disease domains.","ASPIRE trial enrollment exceeded; expects to dose 4th patient in July 2026; safety data to support BLA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-276738","json":"https://secwatch.observer/filing/0001193125-26-276738.json","markdown":"https://secwatch.observer/filing/0001193125-26-276738.md","text":"https://secwatch.observer/filing/0001193125-26-276738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/0001193125-26-276738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:15:18.754748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}